MedTrace Logo

LIBERATE Trial in COVID-19

NCT04334629 · Status: WITHDRAWN · Phase: PHASE4 · Type: INTERVENTIONAL

Last updated 2023-07-25

No results posted yet for this study

Summary

The study aims to evaluate the reduction in severity and progression of lung injury with three doses of lipid ibuprofen in patients with SARS-CoV-2 infections.

Conditions

  • Coronavirus
  • Respiratory Distress Syndrome
  • SARS-CoV Infection

Interventions

DRUG

Ibuprofen

Lipid ibuprofen 200 mg

Sponsors & Collaborators

Principal Investigators

  • Richard Beale, MD · Guy's and St Thomas' NHS Foundation Trust

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-05-26
Primary Completion
2021-05-25
Completion
2021-09-25

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04334629 on ClinicalTrials.gov